Loading condition report…
Loading condition report…
A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
Evidence at a glance
Open any number to go directly to the underlying records.
The report maps directly scoped documents, study registrations, formulations and exact source-reported evidence. Efficacy, treatment and safety conclusions remain unvalidated. Every item links back to preserved source material. Study registrations and dose records describe what researchers reported or planned; they are not treatment advice or proof that an intervention works.
Condition scope
Subtype counts can overlap because one article may discuss more than one condition.
Research map
These are document-level associations. The first group has study-registration or regulatory context; neither group proves efficacy or clinical use.
Mild cognitive impairment context
registered studies · not a treatment claimHow treatment was studied
Routes and dose values below describe registered or published research. They are not prescribing instructions.
What researchers planned or recorded in trial registrations.
No exact dose descriptions were present in this frozen report snapshot.
How the intervention was described as being given in registered studies.
Open a route to see its registrations. Green cards have registry-posted results; yellow cards currently contain a registration only. This is not a conclusion about efficacy or safety.
Source-backed observations from readable publications.
Systematic review: researchers use a documented method to find, select and assess all relevant studies for a specific question.
Meta-analysis: when the studies are sufficiently comparable, their numerical results are combined statistically.
These methods can provide a broader view than one study, but their reliability still depends on the quality and similarity of the included evidence. They do not automatically prove that a treatment works.
No publication-level dosing evidence is available in this frozen snapshot.
How the research was designed
These labels describe the registered study design—not whether the treatment worked. A study can use several methods, so categories may overlap. Protocol categories are deterministic title/type matches and use a multi-label taxonomy. Filters preserve every matching tag while each registration is shown once. Registration is not a result.
Showing 12 of 12 unique registrations. 13 pattern memberships are preserved as badges; counts may overlap.
Research frequency
Counts use the directly scoped, rights-cleared article snapshot. The current year is partial.
Registries
A registration describes the protocol. When posted, source-reported outcomes and safety are preserved on the local Study page.
Browse the complete filtered study catalog →
Showing 12 of 18 directly scoped registrations.
38 enrolled
Open study record84 enrolled
Open study record70 enrolled
Open study record40 enrolled
Open study record821 enrolled
Open study record24 enrolled
Open study recordEnrollment not reported
Open study record1,500 enrolled
Open study record72 enrolled
Open study record140 enrolled
Open study record61 enrolled
Open study record120 enrolled
Open study recordSupporting evidence and regulatory context
Available items are locally preserved, frozen candidates. Funding and related research remain unavailable until a complete relevance-policy-v2 section is frozen; unavailable safety linkage is never presented as zero. Source metadata and safety reports are not efficacy or causality claims.
Frozen 24/09/2026 · 3,918 records · source sync still in progress
Research Narrative Use of cannabidiol (CBD) has been increasing rapidly across the United States, particularly among adults over the age of 55 with mild cognitive impairment and who might be at risk for Alzheimer’s disease (AD). The proposed randomized, placebo-controlled, double-blind trial will examine the effect of CBD biomarkers and behavioral measures associated with the progression of AD over 6 months. The information gained in this research is expected to inform public health about the effects of CBD in this population.
U.S. Government public data · candidate metadata, not a medical claimResearch Narrative Use of cannabidiol (CBD) has been increasing rapidly across the United States, particularly among adults over the age of 55 with mild cognitive impairment and who might be at risk for Alzheimer’s disease (AD). The proposed randomized, placebo-controlled, double-blind trial will examine the effect of CBD biomarkers and behavioral measures associated with the progression of AD over 6 months. The information gained in this research is expected to inform public health about the effects of CBD in this population.
U.S. Government public data · candidate metadata, not a medical claimPROJECT NARRATIVE This administrative supplement application is in response to PA-18-591 and NIH notice, NOT-AG-20-034 about extending the active R01 projects to Alzheimer’s disease and related dementia (ADRD) research. With the increase in the life expectancy of people living with HIV (PLHIV), they face a burden of increased risk of developing Alzheimer’s disease (AD) due to the basal level secretion of toxic proteins such as HIV-Tat. Since there is no effective therapy either for AD or HIV-associated neurocognitive disorders (HAND), we want to test whether our recently discovered CB1 receptor ligand AMG315 with better potency and stability can mitigate neuroinflammation, amyloid, and tangle burden in a comorbidity model of AD and HIV.
U.S. Government public data · candidate metadata, not a medical claimNARRATIVE Little is known about the effects of HIV on Alzheimer's Disease (AD) in the aging HIV population. Likewise, whether cannabis exposure has a positive or negative effect on either condition is not known. Our proposed study will utilize a unique collection of postmortem brain tissues from our parent study to investigate AD-neuropathological changes in cannabis users and non-users who are HIV infected. Our study will lead to an enhanced understanding of relationships between long-term HIV infection and AD, and will stimulate additional research, including evaluation of the potential therapeutic use of cannabis for these diseases.
U.S. Government public data · candidate metadata, not a medical claimPUBLIC HEALTH RELEVANCE: Patients with Alzheimer's disease (AD) often have severe agitation, and we have preliminary data suggesting that dronabinol (a medication derived from the active ingredient in marijuana and FDA-approved for severe lack of appetite) may also be safe and helpful in treating persons with AD and agitation. We propose to test the effect of three weeks dronabinol treatment in 80 patients at Johns Hopkins and McLean Hospitals, assessing primarily whether dronabinol helps agitation but also importantly assessing its safety.
U.S. Government public data · candidate metadata, not a medical claimCurrently there are no effective drugs that prevent the death of nerve cells associated with neurodegenerative diseases such as Alzheimer's. This disease is very complex, and there are many factors that contribute to the patient's demise, yet most drug discovery projects use an approach that only addresses one of the many aspects of the disease pathology. In this proposal, a different approach to identify a drug candidate for AD is proposed, one that is based upon natural products that are known to interact with molecular systems in the brain that are compromised in AD.
U.S. Government public data · candidate metadata, not a medical claimPUBLIC HEALTH RELEVANCE: Patients with Alzheimer's disease (AD) often have severe agitation, and we have preliminary data suggesting that dronabinol (a medication derived from the active ingredient in marijuana and FDA-approved for severe lack of appetite) may also be safe and helpful in treating persons with AD and agitation. We propose to test the effect of three weeks dronabinol treatment in 80 patients at Johns Hopkins and McLean Hospitals, assessing primarily whether dronabinol helps agitation but also importantly assessing its safety.
U.S. Government public data · candidate metadata, not a medical claimNARRATIVE With anti-retroviral therapy (ART), people living with HIV (PLWH) are living a normal life span and are aging, but the extended lifespan, poor ART penetration of the brain, neuroviral replication and chronic neuroinflammation may increase the risk for early onset of age-related neurodegenerative diseases like Alzheimer disease (AD) in PLWH. This proposed study will provide a detail examination of AD-associated neuropathology across age groups in PLWH to identify the underlying mechanisms of neurodegeneration, and whether cannabis use can mitigate early onset of AD-associated neuropathology in PLWH through its reported anti-inflammatory effects. Insights from this research could inform targeted interventions to prevent brain aging and neurodegeneration in PLWH in the United States and throughout the world.
U.S. Government public data · candidate metadata, not a medical claimPUBLIC HEALTH RELEVANCE: Patients with Alzheimer's disease (AD) often have severe agitation, and we have preliminary data suggesting that dronabinol (a medication derived from the active ingredient in marijuana and FDA-approved for severe lack of appetite) may also be safe and helpful in treating persons with AD and agitation. We propose to test the effect of three weeks dronabinol treatment in 80 patients at Johns Hopkins and McLean Hospitals, assessing primarily whether dronabinol helps agitation but also importantly assessing its safety.
U.S. Government public data · candidate metadata, not a medical claimResearch Narrative Use of cannabidiol (CBD) has been increasing rapidly across the United States, particularly among adults over the age of 55 with mild cognitive impairment and who might be at risk for Alzheimer’s disease (AD). The proposed randomized, placebo-controlled, double-blind trial will examine the effect of CBD biomarkers and behavioral measures associated with the progression of AD over 6 months. The information gained in this research is expected to inform public health about the effects of CBD in this population.
U.S. Government public data · candidate metadata, not a medical claimPUBLIC HEALTH RELEVANCE: Patients with Alzheimer's disease (AD) often have severe agitation, and we have preliminary data suggesting that dronabinol (a medication derived from the active ingredient in marijuana and FDA-approved for severe lack of appetite) may also be safe and helpful in treating persons with AD and agitation. We propose to test the effect of three weeks dronabinol treatment in 80 patients at Johns Hopkins and McLean Hospitals, assessing primarily whether dronabinol helps agitation but also importantly assessing its safety.
U.S. Government public data · candidate metadata, not a medical claimShowing 12 of 15 frozen records. Browse the complete set →
Unavailable. Governed relevance linkage is not ready for this frozen snapshot; no absence of records is inferred.
No matching records in this frozen snapshot.
FAERS package linkage is unavailable; zero reports must not be inferred until exact governed medicine links are ready.
Regulatory records
Registry Results
Registry-submitted primary-outcome values are shown with exact local provenance. The service does not infer efficacy, effect direction or a treatment recommendation from these unreviewed values.
The registry has not posted a Results section for these records. A protocol does not show whether the intervention worked.No registry Results section is pinned in this frozen report snapshot.
A registration describes what was planned. It does not show whether the intervention worked.
Safety
The linked evidence is source-reported and remains candidate-only. Contraindications and patient-specific guidance are not yet validated.
Latest additions
The articles, studies and medicine records shown here are fixed to one dated snapshot. Their source identifiers and links were checked, but the platform has not turned registry entries into clinical conclusions.
This condition is normalized as D000544 using Medical Subject Headings 2026.
9,777 source identifiers verified · snapshot record 8bf4e1f379e1...Dates are derived from this report's immutable package pins. A failed refresh does not replace the last good report.
Limits
Showing 12 of 3,869 frozen records. Browse the complete set →